Tianjin Ringpu Bio-Technology Co.,Ltd. (SZSE:300119) shareholders are probably feeling a little disappointed, since its shares fell 8.8% to CN¥11.85 in the week after its latest interim results. Results look mixed - while revenue fell marginally short of analyst estimates at CN¥1.1b, statutory earnings were in line with expectations, at CN¥0.98 per share. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.

After the latest results, the seven analysts covering Tianjin Ringpu Bio-TechnologyLtd are now predicting revenues of CN¥2.76b in 2024. If met, this would reflect a solid 17% improvement in revenue compared to the last 12 months. Per-share earnings are expected to step up 15% to CN¥1.08. In the lead-up to this report, the analysts had been modelling revenues of CN¥2.74b and earnings per share (EPS) of CN¥1.13 in 2024. The analysts seem to have become a little more negative on the business after the latest results, given the minor downgrade to their earnings per share numbers for next year.

The average price target fell 12% to CN¥18.66, with reduced earnings forecasts clearly tied to a lower valuation estimate. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on Tianjin Ringpu Bio-TechnologyLtd, with the most bullish analyst valuing it at CN¥21.00 and the most bearish at CN¥16.50 per share. Still, with such a tight range of estimates, it suggeststhe analysts have a pretty good idea of what they think the company is worth.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. It's clear from the latest estimates that Tianjin Ringpu Bio-TechnologyLtd's rate of growth is expected to accelerate meaningfully, with the forecast 38% annualised revenue growth to the end of 2024 noticeably faster than its historical growth of 8.9% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 12% annually. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Tianjin Ringpu Bio-TechnologyLtd to grow faster than the wider industry.

The Bottom Line

The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Tianjin Ringpu Bio-TechnologyLtd. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. Furthermore, the analysts also cut their price targets, suggesting that the latest news has led to greater pessimism about the intrinsic value of the business.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple Tianjin Ringpu Bio-TechnologyLtd analysts - going out to 2026, and you can see them free on our platform here.

However, before you get too enthused, we've discovered 2 warning signs for Tianjin Ringpu Bio-TechnologyLtd that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.